- Born October 13, 1944. PhD in Biophysics (1973, SCL, Paris-VII University). - Present status: Emeritus Professor, Inserm-Institut Curie. - Address: Inserm U 1021, Institut Curie, Paris-Saclay University, Orsay, France (vincent.favaudon@curie.fr). - Stays Abroad: Post-doctoral fellowship, Fachbereich Biologie, Universität Konstanz, Germany (1974). Visiting Associate Professor of Pharmacology, Harvard Medical School, Dept of Pharmacology, Boston, USA (1983-1984). - Track record: Spectroscopy, kinetics, thermodynamics. Haems & haemoproteins, flavins & flavoproteins (1968-1977). Pulse radiolysis, free radicals, oxygen activation, radiation biology (1975-Present). Antitumor drugs, Chemo-Radiotherapy combinations (1982-2012). Ultrahigh dose-rate “FLASH” Radiotherapy (2006-present). - Executive and Honorary Positions: Founder of Inserm unit U612 (2004). Member (elected) of the Scientific Committee of the Research Section of Institut Curie (1994-2010). Member (elected) of the Board of Directors of Institut Curie (1997-2015). - Teaching Activities 2004-2019: Master of Cancerology and Radiobiology for Radiation Therapists, Paris-XI University. DOREMI International Course in Radiation Biology. E-learning course on cell cycle and DNA damage signalization. Supervision of numerous PhD dissertations. - Publications: 142 original papers in peer-reviewed journals, reviews, monographs and book sections. Over 170 symposium contributions. Over 20 invited conferences on FLASH radiotherapy since 2010.

Giuseppe Felici is graduated in Physics at University of Rome 'La Sapienza' specializing his studies in Medical Physics. Author of more than 60 publications in international peer reviewed journals (H-index 10) and more than 10 national and international patents. He is a reviewer for Physica Medica - European Journal of Medical Physics. Since 2001, he is involved in the design and production of radiotherapy accelerators, contributing to the development of several IORT linac models. Since 2017 he is Scientific Director of SIT.

Dr Celeste Fleta is a research scientist at Instituto de Microelectronica de Barcelona. Her area of work is the development of innovative radiation detectors for medical applications, high energy physics and security. She is specialist in clean room microfabrication processes, design and characterization of microelectronic devices.

Higher Research Scientist at the National Physical Laboratory (UK), and Honorary Research Associate at the University of Birmingham (UK).

Sr. Manager, Flash Research at Varian, a Siemens Healthineers company. Over the past 3 years Michael has led the direction of Flash physics R&D. He was responsible for key technical developments in treatment planning and QA for the FAST-01 and FAST-02 trials. He earned his PhD in physics from the University of California San Diego under the supervision of Professor Steve B. Jiang, PhD, DABR. Before joining the Flash team, Michael worked for Varian as an on-site software engineer in UT Southwestern’s department of Radiation Oncology.

Charles Fouillade is a radiation biologist studying the impact of radiotherapy on normal tissue. His work aims at i) deciphering the physiopathology of lung radiation toxicity and ii) understanding the molecular mechanisms of FLASH radiation therapy in the lung. More info : http://orcid.org/0000-0003-2692-5645

Dr. Richard Frock is an Assistant Professor in the Department of Radiation Oncology, Division of Radiation and Cancer Biology at Stanford University. He received his Ph.D. in Biochemistry from the University of Washington studying A-type nuclear laminopathies in striated muscle and lymphocyte development. Richard then completed his postdoctoral training at Harvard Medical School and Boston Children’s Hospital where he made seminal contributions to the development (HTGTS) and improvement (LAM-HTGTS) of a high-throughput chromosome translocation sequencing technology, which has been used extensively to locate recurrent and widespread DNA double-stranded breaks (DSBs) genome-wide in developing lymphocytes and cancer cells and to reveal the collateral damage associated with using engineered endonucleases for genome editing. His group is continuing to evolve this technology, most recently described as reJoin and Translocation sequencing (HTGTS-JoinT-seq), to aid in developing novel therapeutics and to further reveal the underlying biological responses to various sources of DNA damage. Dr. Frock is a member of the Stanford Cancer Institute (SCI), Maternal and Childhood Health Research Institute (MCHRI), and the Stanford Bio-X Initiative. He is the recipient of the 1st Annual Career Development Award from the Radiation Research Foundation and is a V Scholar for the V Foundation for Cancer Research.

Pascal Froidevaux. P. Froidevaux obtained his PhD degree in 1992 from the University of Lausanne. After two years of postdoctoral study at the University of Western Australia, he joined the Institute of Radiation Physics at CHUV as leader of the radiochemistry group. He worked mostly in the field of radioecology, environmental radioactivity survey and radioanalytical chemistry and carried our several research programs on the migration and bioavailability of radionuclides in natural environments and radionuclides in humans. More recently, the centre of his interests moved to public health projects, such as 210Po in tobacco smoke and its application to tobacco prevention. He is now strongly involved in the CHUV-FLASH project, in which he studies the role of lipids peroxidation as a mechanism involved in the FLASH effect.